Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03340766 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03340766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2018
Completion date
August 14, 2023
Enrollment
31 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory diffuse large b cell lymphoma (dlbcl)